Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.62 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.62 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.62 |
| ▸ | RELA | Q04206 | 3/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | RAB9A | P51151 | 5/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.57 |
| ▸ | MITF | O75030 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | HPGD | P15428 | 2/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.57 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7753018 | 0.98 | KDM4E (0.60) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL1095256 | 0.86 | SMN1; SMN2 (0.46) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL11147962 | 0.86 | NPC1 (0.68) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| Hydrochloric Acid SCHEMBL11215209 | 0.85 | NPC1 (0.66) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL2055271 | 0.85 | DYRK1A (0.58) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL2000313 | 0.85 | NPC1 (0.51) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL1748004 | 0.82 | SMN1; SMN2 (0.63) | SMN1; SMN2LMNANPC1RAB9ATDP1 | |
| SCHEMBL1983363 | 0.81 | PIK3CA (0.64) | KDM4ESMN1; SMN2LMNANPC1RAB9A | |
| SCHEMBL1748181 | 0.81 | KMT2A (0.46) | KDM4ESMN1; SMN2NFKB1NFKB2RELA | |
| SCHEMBL381600 | 0.81 | SMN1; SMN2 (0.64) | KDM4ESMN1; SMN2NFKB1NFKB2RELA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025045777-A1 | INHIBITORS OF PCSK9 | DRAUPNIR BIO APS (DK) | 2025-03-06 | — | — | WO | disclosed |
| CN-119431315-A | PRMT7 target inhibitor and application thereof | 中国药科大学 | 2025-02-14 | — | — | CN | disclosed |
| CN-118791464-B | PRMT7 target inhibitor and application thereof | 中国药科大学 | 2024-11-22 | — | — | CN | disclosed |
| CN-118791464-A | PRMT7 target inhibitor and application thereof | 中国药科大学 | 2024-10-18 | — | — | CN | disclosed |
| CN-116693414-A | Compound with 3CL protease inhibition activity and application thereof | 深圳市小分子新药创新中心有限公司 | 2023-09-05 | — | — | CN | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | ENANTA PHARMACEUTICALS, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| WO-2008142369-A1 | MAGENTA DYES AND INKS FOR USE IN INK-JET PRINTING | FUJIFILM IMAGING COLORANTS LIMITED (GB) | 2008-11-27 | — | — | WO | disclosed |
| WO-2008124393-A1 | BENZOTHIAZOLE DERIVATIVES AND THEIR USE AS PROTEIN KINASE INHIBITORS | IRM LLC (BM) | 2008-10-16 | — | — | WO | disclosed |
| CN-101253171-A | Benzooxazole, oxazolopyridine, benzothiazole and thiazolopyridine derivatives | HOFFMANN LA ROCHE (CH) | 2008-08-27 | — | — | CN | disclosed |
| CN-1243741-C | Quinolinyl and benzothiazolyl PPAR-gamma modulators | TULARIK INC (US) | 2006-03-01 | — | — | CN | disclosed |
| CN-1438998-A | Quinolinyl and benzothiazolyl PPAR-gamma modulators | TULARIK INC (US) | 2003-08-27 | — | — | CN | disclosed |
| US-4534908-A | Water-soluble disazo compounds and new bis-(aminophenoxy)-ethane compounds having fiber-reactive groups as the tetrazo components, and use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-08-13 | — | — | US | disclosed |
| EP-0071168-B1 | WATER-SOLUBLE DISAZO COMPOUNDS AND BIS-(AMINO-PHENOXY)-ETHANE COMPOUNDS WITH FIBRE REACTIVE GROUPS AS TETRAZO COMPOUNDS, PROCESS FOR THE PREPARATION OF THESE COMPOUNDS AND THE USE OF THE DISAZO COMPOUNDS AS DYESTUFFS | HOECHST AKTIENGESELLSCHAFT (DE) | 1985-01-30 | — | — | EP | disclosed |
| US-4394310-A | DIAZOTIZATION, CYCLIZATION | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-19 | — | — | US | disclosed |
| US-4386935-A | Process for producing discharge reserve prints on textile materials with amino-azo-benzene dyes | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-06-07 | — | — | US | disclosed |
| EP-0071168-A2 | Water-soluble disazo compounds and bis-(amino-phenoxy)-ethane compounds with fibre reactive groups as tetrazo compounds, process for the preparation of these compounds and the use of the disazo compounds as dyestuffs | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034684-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | GPBAR1, SLC10A1, NR1H4 | KDM4E 4232/4885SMN1; SMN2 4455/4885NFKB1 2469/4885 |
| US-10689391-B2 | Isoxazole analogs as FXR agonists and methods of use thereof | SLC10A1, NR1H4, GPBAR1 | KDM4E 4346/4885SMN1; SMN2 4330/4885NFKB1 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.